Bayer Ponders Animal Health Future, Still Keen On Diabetes Care
This article was originally published in The Pink Sheet Daily
Executive Summary
The diversified big pharma is continuing to discuss the need for critical mass in the animal health sector, and whether the business should stay within the company, but for now diabetes care is to remain because of the way it generates cash without needing extra investment.